Champix

DRUG4 trials

Sponsors

The Queen Elizabeth Hospital, University Health Network, Toronto, Ottawa Heart Institute Research Corporation, Yuhan Corporation

Conditions

Healthy VolunteerPsychiatric IllnessSmokingSmoking CessationTobacco Use Disorder

Phase 1

Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

CompletedNCT04225052

Yuhan CorporationHealthy Volunteer

Start: 2019-12-19End: 2020-01-14Updated: 2020-01-23

Phase 2

Smoking Termination Opportunity for inPatients

CompletedNCT01141855

The Queen Elizabeth HospitalTobacco Use Disorder

Start: 2008-05-31End: 2011-12-31Updated: 2012-08-08

Phase 4

Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling

CompletedNCT01623505

Ottawa Heart Institute Research CorporationPsychiatric Illness, Smoking Cessation

Start: 2010-06-30End: 2014-06-30Updated: 2017-04-13

Unknown Phase

Smoking Cessation Program in the Preadmission Clinic: The Use of a Teachable Moment

CompletedNCT01243203

University Health Network, TorontoSmoking

Start: 2007-11-30End: 2011-11-30Updated: 2017-05-08

Related Papers

Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial

BMC Medicine2016-05-2753 citations

Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients.

2012-09-1921 citations